Child Gut Health Test
The Child Gut Health Test uses shotgun metagenomic sequencing of stool to profile the paediatric gut microbiome, reporting age-stratified abundance of beneficial bacteria (Bifidobacterium, Lactobacillus, Akkermansia, Faecalibacterium), pathobionts, alpha diversity, and SCFA producers.
4
Biomarkers
Stool
Sample
14–21 business days
Turnaround
No
Fasting
What is the Child Gut Health test?
The Child Gut Health Test uses shotgun metagenomic sequencing of stool to profile the composition, diversity, and functional potential of a child's gut microbiome. It is ordered by practitioners working with children who have persistent gastrointestinal symptoms — colic, reflux, constipation, diarrhoea, or abdominal pain — atopic conditions such as eczema or food sensitivities, recurrent infections, or developmental and behavioural concerns where gut-brain-axis involvement is suspected. The test is also used proactively to assess microbiome development in children with a history of antibiotic exposure, caesarean delivery, formula feeding, or prematurity. Results provide a compositional snapshot rather than a static diagnosis. The paediatric gut microbiome is dynamic, reflecting the child's age, diet, antibiotic history, and environment, so the test informs targeted dietary, probiotic, and lifestyle interventions and guides decisions about further investigation — stool culture, calprotectin, coeliac serology, or allergy testing — when symptoms persist. Practitioners interpret the findings within the child's clinical context and developmental stage, using the microbiome profile to personalise nutrition and functional support rather than to label or treat asymptomatic colonisation.
What does the Child Gut Health test measure?
The paediatric gut microbiome develops rapidly from birth through early childhood, shaped by mode of delivery, feeding method, antibiotic exposure, and diet. Bifidobacterium species dominate the breastfed infant gut and support immune education, epithelial barrier maturation, and short-chain fatty acid production. Lactobacillus species contribute to pathogen exclusion and mucosal immunity. Akkermansia muciniphila maintains mucus-layer integrity, and Faecalibacterium prausnitzii — a butyrate producer — becomes more prominent as the diet diversifies. The composition at each developmental stage reflects the child's diet, environment, and immune maturation rather than a single static 'optimal' profile.
Relative abundance of beneficial taxa is interpreted within the context of the child's age, diet, and clinical presentation. Low Bifidobacterium in an exclusively breastfed infant may prompt evaluation of maternal diet, antibiotic history, or feeding difficulty. Reduced diversity or beneficial taxa in an older child with persistent gastrointestinal symptoms, eczema, or recurrent infection may inform probiotic, dietary, or microbiome-targeted interventions. Because reference distributions are method- and cohort-specific, results guide functional and dietary support rather than serving as diagnostic thresholds.
The developing gut contains a shifting balance of commensal and potentially pathogenic organisms. Many pathobionts are present at low abundance without causing disease but can overgrow during antibiotic disruption, dietary stress, or immune immaturity. Clostridioides difficile colonisation is common in infants without toxin-mediated disease. Opportunistic Enterobacteriaceae can bloom after antibiotic courses or during weaning. The presence of a pathobiont is interpreted alongside its abundance, the child's symptoms, and the overall microbial community structure.
Detection of pathobionts informs targeted intervention only when correlated with clinical findings — persistent diarrhoea, abdominal pain, failure to thrive, or atopic disease. Asymptomatic colonisation does not warrant antimicrobial therapy. Results guide dietary modification, probiotic or prebiotic support, and the decision to pursue stool culture, toxin assay, or further gastrointestinal investigation.
Alpha diversity quantifies the richness and evenness of the gut microbial community. Diversity increases from the neonatal period through toddlerhood as diet and environmental exposures broaden. Lower diversity in early life is physiological when the infant is breastfed and Bifidobacterium-dominant; reduced diversity in an older child may reflect antibiotic exposure, restricted diet, or dysbiosis. High diversity is generally associated with resilience and metabolic health, but it must be interpreted within the child's age and feeding context.
Diversity indices guide the practitioner's understanding of microbiome maturation and resilience. Unexpectedly low diversity in a toddler or school-age child with chronic gastrointestinal symptoms, atopy, or recurrent infection may prompt dietary diversification, probiotic therapy, or investigation of underlying inflammatory or immune conditions. Diversity alone does not diagnose disease but contextualises the functional and compositional findings.
Short-chain fatty acids — butyrate, acetate, and propionate — are microbial fermentation products of dietary fibre that fuel colonocytes, modulate immune signalling, maintain epithelial barrier integrity, and influence systemic metabolism. SCFA-producing taxa become more abundant as the child's diet includes complex carbohydrates and fibre. In breastfed infants, Bifidobacterium-derived acetate predominates; butyrate producers such as Faecalibacterium increase during weaning and dietary diversification.
Reduced SCFA-producer abundance in an older child may correlate with low dietary fibre intake, chronic constipation, inflammatory gastrointestinal symptoms, or immune dysregulation. Results inform dietary counselling — increasing prebiotic fibre, resistant starch, and diverse plant foods — and may guide probiotic or postbiotic supplementation. SCFA-producer abundance is a functional marker rather than a diagnostic threshold and is read alongside diversity and beneficial-taxon metrics.
Why is the Child Gut Health test ordered?
- Investigation of persistent gastrointestinal symptoms in infants and children — colic, reflux, constipation, diarrhoea, or abdominal discomfort not explained by standard evaluation
- Assessment of children with atopic disease — eczema, food sensitivities, or allergic tendencies — where gut dysbiosis is suspected to contribute to immune dysregulation
- Evaluation of recurrent infections or prolonged antibiotic courses, to guide microbiome restoration and probiotic or dietary intervention
- Monitoring microbiome development in children with a history of caesarean delivery, formula feeding, prematurity, or neonatal intensive care, particularly when combined with gastrointestinal or atopic symptoms
- Support for children with developmental, behavioural, or neurological concerns where gut-brain-axis involvement is being explored as part of a comprehensive functional approach
- Prebiotic and probiotic therapy guidance in children undergoing dietary intervention for gastrointestinal, immune, or metabolic conditions
- Follow-up assessment after microbiome-targeted intervention — dietary modification, probiotic therapy, or antibiotic stewardship — to document compositional change and guide next steps
Sample collection and turnaround
Sample type
Stool
Fasting required
No
Collection method
At-home collection kit
Turnaround
14–21 business days
Collection notes
Parents or carers collect a small stool sample at home using the kit provided by Tiny Health, which includes a collection device, preservative tube, and prepaid return mailer. Sample from a fresh nappy or clean collection container; avoid contact with urine or toilet water. Refrigerate immediately after collection and ship with the enclosed cold pack within 24–48 hours. Document the child's age, diet (breastfed, formula-fed, or mixed; weaning status), and any antibiotic, probiotic, or prebiotic use in the preceding four weeks.
Specimen requirements
Approximately one pea-sized stool sample in the provided preservative tube. Microbial DNA is stable in the kit's preservative, but timely refrigeration and shipping preserve specimen quality. Follow the kit instructions precisely.
What can affect Child Gut Health results?
Antibiotics cause acute and sometimes prolonged shifts in microbial composition, reducing diversity and beneficial taxa and allowing pathobiont overgrowth. A sample during or immediately after a course may not reflect baseline microbiome status; a minimum two-week interval post-antibiotic is recommended where clinically feasible.
Viral or bacterial gastroenteritis transiently disrupts the microbiome. Testing during acute illness captures the perturbed state rather than the child's baseline; defer sampling until symptoms resolve unless the acute dysbiosis itself is the clinical question.
The microbiome shifts within days to weeks in response to dietary change. If the test is ordered to assess baseline composition, sample before starting an elimination diet; if it is ordered to monitor response, allow sufficient time (typically four to six weeks) for microbial adaptation.
Probiotics may appear in the sequencing data if the child is actively supplementing, and prebiotics alter microbial fermentation patterns. Document all supplements and their timing; some practitioners choose to sample before starting therapy to establish a baseline, others sample on therapy to assess engraftment and response.
Microbial DNA is stable, but live organism ratios can shift if the sample is left at ambient temperature for extended periods. Follow the kit's collection and shipping instructions — typically refrigerate immediately and ship with the provided cold pack within 24–48 hours — to maintain specimen integrity.
What do Child Gut Health results mean?
Elevated
High relative abundance of pathobionts or low-diversity dysbiosis: consider recent antibiotic exposure, dietary insufficiency (low fibre, restricted variety), underlying inflammatory or immune conditions, or environmental stressors. Correlate with clinical symptoms — persistent diarrhoea, failure to thrive, atopic flares — and use results to guide targeted dietary intervention, probiotic or prebiotic therapy, and further investigation (stool culture, calprotectin, coeliac or allergy testing) where indicated.
Normal
Age-appropriate diversity and beneficial-taxon balance: supports the absence of major dysbiosis but does not exclude other causes of the child's symptoms. Continue standard clinical investigation and use the microbiome result to inform preventive dietary and lifestyle recommendations rather than to conclude that no intervention is needed.
Reduced
Low beneficial-taxon abundance or reduced SCFA producers: often reflects inadequate dietary fibre, restricted food variety, or post-antibiotic microbiome depletion. In breastfed infants, low Bifidobacterium may prompt maternal-diet or breastfeeding-support review. Intervention includes dietary diversification, prebiotic-rich foods, and strain-specific probiotics. Follow-up testing documents recovery and guides ongoing support.
Note: The paediatric gut microbiome is developmentally dynamic; reference ranges are age-, diet-, and assay-specific, so results are not interchangeable across laboratories or directly comparable to adult norms. A single sample is a snapshot; serial testing better captures trajectory and response to intervention. Metagenomic sequencing reports taxonomic composition and inferred functional potential but does not directly measure metabolites, toxins, or host immune markers, so integrate findings with clinical symptoms, growth parameters, and, where indicated, faecal calprotectin, stool culture, or serology. Asymptomatic colonisation by pathobionts does not mandate antimicrobial therapy. The test is a functional and educational tool; it guides personalised nutrition and microbiome support but is not a stand-alone diagnostic for inflammatory bowel disease, infection, or allergy.
Frequently asked questions
The test uses shotgun metagenomic sequencing to profile the composition, diversity, and functional potential of a child's gut microbiome, reporting beneficial bacteria, pathobionts, alpha diversity indices, and short-chain fatty acid producers, all interpreted with age-stratified paediatric reference cohorts.
How to access the Child Gut Health test
The Child Gut Health reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Bäckhed F, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. (2015)
- Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergol Int. (2017)
- Milani C, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev. (2017)
- Voreades N, et al. Diet and the development of the human intestinal microbiome. Front Microbiol. (2014)
- Huttenhower C, et al. Structure, function and diversity of the healthy human microbiome. Nature (Human Microbiome Project Consortium). (2012)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.